Clinical trial · Observational
Capillary Blood Accuracy
NCT06544070CI-TRIAL-00079662CAPYBARAwithdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Why stopped (as posted): Change in trial pipeline. Study no longer required.
Summary
Brief summary (as posted)
Entia is a health technology company that has developed a blood testing device called Entia Liberty, which analyses blood collected by a finger prick. Entia is sponsoring this research study to compare the results from Entia Liberty finger prick tests to results from the gold-standard laboratory analyser that tests blood from the arm, port, or PICC line.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Entia Liberty System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Phase 1
- description
- Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.0 x109/L who can be consented within 24 hours of the result. Participants will donate one finger prick sample up to once per day to be tested on the Liberty device.
- interventionNames
- Device: Entia Liberty System
- label
- Phase 2
- description
- Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.5 x109/L who can be consented within 24 hours of the result. Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session.
- interventionNames
- Device: Entia Liberty System
- label
- Phase 3
- description
- Participants who are undergoing a routine venous draw as part of the standard of care as part of SACT toxicity monitoring. Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old at the time of study entry * Patients undergoing systemic anti-cancer therapy (SACT) * Patients capable of providing written informed consent * Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care Additional inclusion criteria: * Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting * Phase 2 (Low count data): Neutrophil Count ≤ 1.5 x109/L within 24 hours preceding consenting Exclusion Criteria: * History or current diagnosis of haematological malignancy * Inadequate use and understanding of the English language, requiring a translator
References
Publications (0)
Data not yet available
No reference posted for this study.